Option Care Health (OPCH) saw a 3.2% increase in its stock price after Morgan Stanley gave it an ‘Overweight’ rating with a $35 price target. Analyst Erin Wright’s bullish view was based on the company’s leading position in home infusion services. The market reacted positively, indicating the news was significant. However, previous concerns over contract negotiations for the drug Stelara had caused a 3.1% drop. Despite this, OPCH is up 22.3% this year but still below its 52-week high. Investors who bought 5 years ago would have doubled their investment. Consider exploring promising growth stocks like OPCH.

Read more at StockStory: Option Care Health (OPCH) Stock Is Up, What You Need To Know